Immunogenicity in Biological DMARDS

Speciality: Rheumatology

Description:

A warm welcome to all the medical professionals in this interesting session on Immunogenicity in Biological DMARDS
Immunogenicity in biological disease-modifying antirheumatic drugs (DMARDs) is a critical factor influencing their efficacy and safety in treating autoimmune conditions like rheumatoid arthritis and psoriatic arthritis. Biological DMARDs, such as TNF inhibitors, interleukin inhibitors, and B-cell depleting agents, can provoke immune responses in patients, leading to the production of anti-drug antibodies (ADAs). These ADAs can reduce the therapeutic effectiveness of the biologic, potentially causing loss of response or treatment failure. For instance, ADAs against infliximab and adalimumab are well-documented and can necessitate switching to another biologic.
Managing immunogenicity involves several strategies to maintain drug efficacy and patient safety. Co-administration of methotrexate or other immunosuppressants can reduce the incidence of ADAs by modulating the immune response. Regular monitoring of drug levels and ADAs helps to identify patients at risk of immunogenicity-related issues early. Dose adjustments, switching to less immunogenic biologics, or employing drug-tolerant assays are additional measures to mitigate the impact of ADAs. Understanding and addressing immunogenicity are vital for optimizing long-term treatment outcomes with biological DMARDs.
Therefore, get an overall knowledge of immunogenicity in biological DMARDS
 

See More Webinars @ Hidoc Webinars